DIGNITANA PRESERVING DIGNITY OF UFE Chairman: CEO: Listing (ticker): Market capitalisation: Website: Semmy Ri.ilf Jan Richardsson Nasdaq First North (DIGN) SEK 320 m (Price SEK 19, April 4. 2016) www.dignitana.com Strictly confidential STOCKHOLM CORPORATE FINANCE ABOUT DIGNITANA Dignitana AB (pub,' ("Dignitana" or the "Company"), founded 2007, is a world leader in medical scalp cooling technology and the manufacturer of the DigniCap scalp cooling system. DigniCap reduces hair loss when patients are going through chemotherapy and has been used world- wide for many years. Approximately 400 systems have been delivered worldwide and more than 15,000 patients have been treated. December 2015 represented a significant breakthrough for the company when FDA clearance for the Dignicap system was received. The DigniCap scalp cooling system was cleared for use in women with breast cancer in the U.S. To date, contracts have been signed with ten cancer centers across the United States (March-16). Dignitana is listed on the NASDAQ First North Stock Exchange since 2011. BUSINESS CONCEPT Dignitana's business concept is to develop, produce and market scalp- cooling technology. THE MARKET Breast cancer is the most common malignancy in women worldwide. Although the majority of women will survive the disease, treatment often includes chemotherapy. Hair loss remains an almost universal side effect of chemotherapy and is rated by breast cancer patients as one of the most distressing side effects of treatment, affecting qual- ity of life, return to work, and self-image. Some clinical studies indi- cate that as many as 5% of the patients refuse chemo therapy in fear of hair loss. Approximately 230,000 new breast cancer patients are diagnosed per year in the United States of which approximately 60% can use Digni- Cap. Each patient receives on average 5 cycles of chemotherapy. The market potential for this particular segment in the USA is approx. 700 0